SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novo Nordisk A/S and Protagonist Therapeutics, Inc. have demonstrated contrasting approaches to SG&A efficiency.

Novo Nordisk A/S: A Steady Climb

From 2014 to 2023, Novo Nordisk A/S has seen a consistent increase in SG&A expenses, growing by approximately 130%. This reflects their strategic investments in expanding market reach and enhancing operational capabilities. By 2023, their SG&A expenses reached a peak, indicating robust growth and market penetration.

Protagonist Therapeutics, Inc.: A Different Path

Conversely, Protagonist Therapeutics, Inc. has experienced a more modest increase in SG&A expenses, rising by nearly 1,700% over the same period. This dramatic rise, albeit from a smaller base, highlights their aggressive push into the market, focusing on innovation and development.

These trends underscore the diverse strategies employed by pharmaceutical companies in managing operational costs while striving for market leadership.